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Background/aim: The COVID-19 pandemic is a unique challenge to the care of patients with hematological malignancies. We aim to
provide supportive guidance to clinicians making individual patients decisions during the COVID-19 pandemic, in particular during
periods that access to healthcare resources may be limited.
Conclusion: This review also provides recommendations, which are convenient in evaluating indications for therapy, reducing
therapy-associated immunosuppression, and reducing healthcare utilization in patients with specific hematological malignancies in
the COVID-19 era. Specific decisions regarding treatment of hematological malignancies will need to be individualized, based on
disease risk, risk of immunosuppression, rates of community transmission of SARS-CoV-2, and available local healthcare resources.
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1. Introduction
At the end of 2019, Wuhan city, the capital of Hubei
province in China, became a center of an outbreak of
pneumonia of unknown cause. By January 2020, Chinese
scientists had identified a novel coronavirus of zoonotic
origin, severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2; previously known as 2019-nCoV), from
these patients with virus-infected pneumonia. This
infection was named coronavirus disease 2019 (COVID19) by the WHO and is now spreading worldwide [1]. As
widespread community transmission becomes likely, it
has posed an unprecedented health emergency. As of 31
December 2020; 85.1 million cases of COVID-19 have been
confirmed resulting in 1.84 million deaths worldwide 1.
Avoiding exposure by adhering to recommended hygiene
procedures, isolation of SARS-CoV-2-infected individuals,
and social distancing especially for risk groups are
currently the main prevention strategies utilized in most
countries [2].
Patients with hematological malignancies are given
cytotoxic therapies, usually administered with curative
intent and management of these patients during the
current pandemic of COVID-19 is challenging [3].
Hematologic cancer patients require special attention and
decision making regarding therapy during the COVID-19
pandemic and needs specialized consideration. It is
important to note that, the quality of care for these
patients were also affected and strategies are required to
deliver the best care during this pandemic.
Herein, we reviewed some of recommendations to
help with the management of patients with hematologic
1

malignancies as well as the evidence when available.
Although data regarding patients with hematological
malignancies are scarce, the considerations for care
modification consist of oral and/or outpatient choices,
protocols that decrease the risk of cytopenias and
postponement of treatment if possible. Clinical study
enrollment is significantly limited, and the risk-benefit
ratio of experimental treatments and their required
logistics must be reconsidered. In the present paper, we
intended to delineate the best practices for myeloid and
lymphoid neoplasms as well as multiple myeloma during
the current COVID-19 pandemic.
2. General considerations and supportive care
Whether the risk of contamination with SARS-CoV-2 is
higher in the inpatient or outpatient setting for patients
with hematological malignancies depends on COVID-19
incidence in the local community [4]. Self-isolation may
enable patients to delay or avoid COVID-19 and this may
be of critical importance following chemotherapy. The
high risk of nosocomial spread of SARS-CoV-2 in hospital
settings is known and also concerns about overwhelming
inpatient capacity limitations are well known [5].
In our center, we have focused on patient and
caregiver education about the importance of social
distancing, hand hygiene, and masking. Patients are
confined to one caregiver and no visitors are allowed in to
inpatient unit. In addition, entrance into our center has
been closed to a single point, at which all patients, staff,
and caregivers are screened; those with symptoms
concerning for COVID-19 are instructed to COVID-19

Website: https://www.worldometers.info/coronavirus [accessed 18 November 2020].
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outpatient clinic for testing. Patients with known
respiratory symptoms and fever are referred to the
emergency room. Outpatient clinics started to work with
telephone
appointments
or
video-conferencing
arrangements wherever these were felt to be acceptable.
Routine testing of asymptomatic patients for SARSCoV-2 is particularly challenging. Most experts
recommend screening cancer patients for SARS-CoV-2
and the test results should be negative before initiation of
the chemotherapy regardless of whether fever or
respiratory symptoms are present [2]. If an immediate
treatment is needed, standard therapy should be
administered in a COVID-19 positive environment.
However, testing capacity and availability of these tests
are country dependent.
Most experts recommended increased use of
granulocyte colony stimulating factor (G-CSF) and
antibiotic prophylaxis routinely to reduce admissions for
febrile neutropenia (FEN) in the current situation [4].
There are also some theoretical concerns about the
exacerbation of SARS-CoV-2 respiratory effect with
filgrastim, but as of yet there is no contraindication to GCSF support in patients anticipated to become FEN.
Bacterial secondary infection can complicate viral
infections, a situation well known in influenza, and also
plausible for SARS-CoV-2. Vaccination against
Streptococcus pneumonia should be recommended to
immunocompromised patients but this needs to be worth
investigating in clinical trials [5]. In our center, we
recommend all lymphoma and myeloma patients receive
routine influenza and pneumococcal vaccination.
There is no shown instance of SARS-CoV-2
transmission through blood products, but most
transfusion societies call for conservative transfusions
policies in strict adherence to evidence-based guidelines
for patient’s blood management in the presence of
decreased donor availability [5]. For patients without
symptomatic anemia or bleeding complications, consider
decreasing the hemoglobin and platelet thresholds to 7
g/dL and 10 x 109/µL, respectively. According to the
American
Society
of
Hematology
(ASH)
recommendations, antifibrinolytics can be given for
patients requiring frequent platelet transfusion and/or
platelet-transfussion-refractory patients2.
Early discussions about goals of care are important in
this pandemic era which may lead to increased
complications and comorbidities among patients with
cancer, who are elderly or have associated chronic
disabling diseases [4].
3. Myeloid neoplasms
3.1. Acute myeloid leukemia
As 50%–75% of patients with acute leukemia are febrile
at diagnosis, they may encounter to the problem of missed

or delayed diagnosis across pandemic period (5). In
addition, most patients may suffer from postponement of
chemotherapy, due to a limited isolation beds and blood
products. Delay in chemotherapy initiation may
unfavorably affect prognosis, especially in young (<60
years-old) leukemia patients with favorable- or
intermediate-risk disease [5].
All the newly diagnosed patients with acute myeloid
leukemia (AML) should be screened for SARS-CoV-2
regardless of symptoms, including baseline CT of the chest
prior to induction as well as consolidation treatment if
indicated. The overall treatment of those patients should
not change during the COVID-19 pandemic with a few
caveats [6].
3.1.1. Induction therapy
While newly diagnosed AML is considered treatment of
emergency in most cases, intensive induction
chemotherapy should still be preferred for eligible
patients with 7+3 (cytarabine plus anthracycline) or a
similar one. According to recommendations of Seattle
group, lower-intensity therapies such as venetoclax with
hypomethylating agents (HMA/VEN) or low-dose
cytarabine are given to the patients for administering
outpatient induction [4]. However, Paul and his colleagues
from MD Anderson Cancer Center (MDCC) generally
recommend these therapies primarily for patients aged
>60 years or those deemed unfit for intensive
chemotherapy [6]. Although the regimens have not been
compared with high-intensity therapy and are not
typically suggested for patients aged <60 years who are
otherwise fit for intensive therapy, they may be
considered in areas with high incidence of COVID-19 cases
to minimize transfusion and utilization of inpatient beds
[6]. It is important to note that there is no evidence that
HMA/VEN is less toxic than standard induction therapy
and patients experience long phases of aplasia, requiring
close follow-up with routine blood counts. MDCC group
recommended a bone marrow evaluation around day 14–
21 during the first cycle to reduce the period of
myelosuppression with VEN combinations. If there is no
morphological evidence of leukemia, VEN may be
withdrawn and administration of G-SCF can be considered
to fasten neutrophil recovery [6].
Based on our knowledge, AML induction therapy does
not primarily influence the lymphocytic cells and patients
are more vulnerable to bacterial and fungal rather than
viral infections. Prophylactic antimicrobials should
generally include levofloxacin, posaconazole, and
acyclovir in the prolonged neutropenia setting.
3.1.2. Consolidation therapy
AML patients in complete remission (CR) undergoing
consolidation/post-remission therapy should receive
outpatient care when possible. European Hematology
Association (EHA) recommends only postponing the

American Society of Hematology (2020). Coronavirus Disease (COVID-19) and Acute Myeloid Leukemia: frequently asked questions
[online]. Website: https://www.hematology.org/covid-19/covid-19-and-acute-myeloid-leukemia [accessed 18 November 2020].
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consolidation chemotherapy until the virus is cleared in
COVID-19 positive patients. With regard to the dosage,
intermediate-dose cytarabine (1.5 g/m2) is recommended
to COVID-19 positive but also to COVID-19 negative AML
patients due to the lack of overall survival (OS) benefit
with the higher dose of 3 g/m2. In this regard, the day
1/2/3 schedule should be preferred over the 1/3/5
schedule with a view to decreasing the number of cycles
to three instead of four. The addition of GCSF with this
condensed cytarabine schedule has been reported to
shorten the time to neutrophil recovery, risk of infection,
duration of hospitalization and platelet transfusion
requirement3.
Consolidative allogeneic hematopoietic stem cell
transplantation (AHSCT) is recommended for patients
with intermediate or high-risk genomic characteristics,
but availability is currently limited [4]. In general,
however, if a transplant candidate is diagnosed with
COVID-19 a postponement of at least three months is
advisable, in accordance with European Society for Blood
and Marrow Transplantation (EBMT) and European
Centre for Disease Prevention and Control (ECDC)
recommendations [2]. However, this is not always
possible due to the risk of progression of the underlying
leukemia. Therefore, in patients with high-risk disease,
AHSCT should be deferred until the patient is
asymptomatic and has two negative SARS-CoV-2 PCR
swabs taken at least 24-h apart. The potential
contribution of anti-SARS-CoV-2 antibody detection is
presently unclear but should be done if available.
Cryopreservation of donor cells prior to the start of
conditioning should be preferred before proceeding to
transplant, which may require an extra cycle of
consolidation therapy4.
3.1.3. Maintenance therapy
Maintenance therapy should be offered particularly for
patients who may be unable to receive their intended
intensive consolidation courses. Based on the results of
the QUAZAR maintenance trial, oral azacitidine improved
relapse-free survival (RFS) and OS in patients being ≥55
years who had previously achieved CR with intensive
induction therapy [7]. Given the deferral in AHSCT during
COVID-19 pandemic, maintenance azacitidine ± VEN
(NCT0406226) should be suggested after patients have
completed consolidation therapy while awaiting AHSCT
as an alternative post-consolidation approach (for 1–2
years) in order to maintain remission [6].

3.1.4. Treatment of relapsed/refractory AML
Many clinical trials have intermitted enrollments, so
standard salvage regimens are recommended if unable to
access a clinical trial. Intensive re-induction for salvage
are still recommended, but the potential benefit must be
weighed against the hardship for patients admitted for
prolonged hospital stay and the shortage of blood
products. ASH recommended for patients without
proliferative disease or significant transfusion
dependence to consider postponing the chemotherapy 5.
Some centers are resuming to prioritize clinical trials for
this patient population. Also patients should undergo
AHSCT if clinically indicated and safe [7,8].
Genomic testing should be done at the time of relapse
to pinpoint the efficacy of approved targeted agents such
as for Isocitrate dehydrogenase-1 (IDH-1), IDH-2, or
farnesyl transferase-3 (FLT-3) mutations [6]. Utilizing an
outpatient, lower-intensity regimen alone or in
combination with targeted therapies whenever available
should be preferred. IDH inhibitors, ivosidenib or
enasidenib may be effective in AML with IDH1 or IDH2
mutations, respectively. Both inhibitors play a role as
differentiating agents with the occurrence, in 10%–20%
of patients, of a differentiation syndrome, which requires
immediate corticosteroid administration and intensive
care support [5]. There is no publication in the literature
about the risk of severe respiratory failure in patients
received these agents and infected by SARS-CoV-2.
3.2. Acute promyelocytic leukemia
Patients with newly diagnosed low-risk acute
promyelocytic leukemia (APL) should be treated with the
combination of all-trans retinoic acid (ATRA) and arsenic
trioxide (ATO) as per standard protocol. High-risk APL
patients should be given cytoreductive chemotherapy in
addition to ATRA and ATO as per standard protocol [6].
APL patients at high risk of differentiation syndrome
can also be treated with prophylactic dexamethasone but
the depth of lymphopenia is of unknown risk in relation to
COVID-19.
3.3. Myelodisplastic syndrome
Myelodisplastic syndrome (MDS) was diagnosed often in
elderly population with a median age of 68 years at
diagnosis. Elderly patients are more likely to have
comorbidities compromising the immune system and this
cause to develop high risk of severe COVID-19. But also
there are no published data yet indicating that patients
with MDS or related conditions are more prone to COVID19 than patients with normal bone marrow function.

European Hematology Association (2020). Recommendations for specific hematologic malignancies, AML and COVID-19 pandemic
[online].
Website:
https://ehaweb.org/covid-19/covid-19
recommendations/recommendations-for-specific-hematologicmalignancies/ [accessed November 2020].
4 European Society for Blood and Marrow Transplantation (2020). Coronovirus disease COVID-19 Recommendations [online].
Website:
version
12-December
2,
2020.
https://www.ebmt.org/sites/default/files/2020-12/EBMT%20COVID19%20guidelines%20and%20summary%20v.13.pdf [accessed 2 December 2020].
5 American Society of Hematology (2020). Coronavirus Disease (COVID-19) and myeloproliferative neoplasms: frequently asked
questions [online]. Website https://www.hematology.org/covid-19/covid-19-and-myeloproliferative-neoplasms. [accessed 14
November 2020].
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However, in the presence of the neutropenia and
functional neutrophil defects among patients with MDS,
there has been an increased risk of bacterial and fungal
infections to a much greater than the risk of viral
infections.
For patients with a newly diagnosed MDS during the
COVID-19 pandemic, selection of therapy should depend
on a risk-adapted approach using the revised
international prognostic scoring system (IPSS) and
following standard guidelines [6].
For patients with lower-risk MDS (IPSS-risk(R) score
<3.5), the clinicians should consider to reduce
transfusions and improve quality of life (QoL). In patients
who are transfusion-independent, initiation of therapy
should be postponed to minimize the need for clinic visits
and viral exposure. Therapy with erythropoietinstimulating agents (ESA) may result in a net decrease of
transfusion needs [6].
For patients with higher-risk MDS (IPSS-R score ≥3.5)
treatment should be initiated with HMA without delay,
and dose adjustment. HMAs should be continued to
prevent the progression of disease to AML if they are
already responding [6]. Despite of the potential risk of
aggravating cytopenias with HMA during the first two
cycles of treatment, the response to HMA in ultimate
recovery of cytopenias and favorable impact on survival
offsets this risk in patients with higher-risk MDS [6].
Intensive therapy can be considered for patients with
higher-risk MDS in whom HMA have failed in spite of the
higher risk of prolonged myelosuppression, infections,
and the potential increased mortality in the time of
COVID-19 [5,6]. The management will be challenging
given the absence of approved therapies in this population
and clinical trials may represent the only treatment
option. AHSCT may still be feasible but given the potential
expected delays of AHSCT during the COVID-19 pandemic,
bridging therapy may be needed. Treatment with low
doses of cytotoxic agents such as cladribine or clofarabine
with low-dose cytarabine should only be preferred in
selected patients with higher-risk MDS and normal
karyotype, provided COVID-19 swab testing is negative
[5,6].
3.4. Myeloproliferative neoplasms
Until now, there is too limited data about patients with
myeloproliferative neoplasm (MPN) who were infected by
SARS-CoV-2. It is clear that nonimmunosuppressive drugs
including low-dose aspirin, phelobotomy, hydroxyurea
(HU), anagrelide, and interferons (IFN) should be
continued since they reduce the risk of short-term
complications such as thrombosis, bleeding, diseaserelated symptoms, and splenomegaly [4]. Therefore, ASH
is not recommending any adjustments to the
aforementioned therapies in someone without/without
COVID-19 but suggesting to initiate cytoreductive

treatments weighing the risk and benefits for patients
with
polycythemia
vera
(PV)
and
essential
thrombocythemia (ET)6.
Phlebotomy is initiated for newly diagnosed patients
with PV, but the other issue is that clustering large groups
into waiting areas for phlebotomy has the potential risk to
facilitate the spread of the COVID-19. Therefore, it’s
recommended to consider extending the interval between
blood draws to monitor counts in order to defer
outpatient visits. JAK inhibitors (JAKi) have also been
commonly used as part of effective treatment for MPN.
Initiation of JAKi (ruxolitinib) may result in worsening
anemia early in therapy and may cause atypical infections.
The abrupt discontinuation of JAKi in successfully
controlled patients with MPN may lead to weakness,
progressive splenomegaly, or infrequently cytokine
storm, and altogether these can exacerbate the clinics of
patients who are infected with SARS-CoV-25. On the other
hand, the global phase III RUXCOVID clinical trial
evaluating ruxolitinib in combination with standard care
for the treatment of cytokine storm triggered by COVID19 has been initiated (NCT04362137). For JAKi responder
patients with MPN, treatment should be continued but if
JAKi therapy is not considered, it is recommended to
postpone until after the peak of the COVID-19 pandemic
has declined.
AHSCT is currently suggested to patients with highrisk myelofibrosis (MF) according to Dynamic
international prognostic scoring system (DIPSS)-Plus or
equivalent after carefully weigh the risks and benefits.
However, based on the ASH recommendations, work up
for AHSCT can proceed but transplant would be deferred
until the risk of COVID-19 has subsided5.
3.5. Chronic myeloid leukemia
Chronic myeloid leukemia (CML) treatment depends on
the administration of continuous BCR-ABL tyrosine
kinase inhibitors (TKIs). To the best of our knowledge,
patients with CML are not at a high risk of infection due to
underlying disease or BCR-ABL TKIs. Therefore, in newly
diagnosed CML, delayed initiation of TKI therapy is not
recommended because uncontrolled leukocytosis might
aggravate lung injury and gas exchanges in the event of
COVID-19 infection. CML progression to advanced-phases
may be even more important risk due to postponed
initiation of TKI.
For newly diagnosed patients, the side effect profiles of
each TKIs should be evaluated in the presence of
symptoms consistent with SARS-CoV-2, such as lung
damage, cardiomyopathy, cardiac arrest, diarrhea, and
thrombotic events. All these may be worsened with TKIs
that can cause similar toxicities and dismal outcomes of
COVID-19 [6]. Therefore, newly diagnosed patients with
CML should be tested with nasopharyngeal swab. If they
have any active infection, TKIs should be held to decrease

American Society of Hematology (2020). Coronavirus Disease (COVID-19) and myeloproliferative neoplasms: frequently asked
questions [online]. Website https://www.hematology.org/covid-19/covid-19-and-myeloproliferative-neoplasms. [accessed 14
November 2020].
6

2802

CENGİZ SEVAL et al. / Turk J Med Sci
additional lung stress during infection and recovery [6].
There is no data suggesting that any of the TKI currently
approved for first line therapy led to a greater or lower
risk of COVID-19 or worse outcome. Some experts advised
to continue TKI treatment in the presence of nonsevere
confirmed COVID-19; in case of severe course of COVID19, TKI interruption should be handled case-to-case
basis7.
For patients with CML on TKIs, prophylactic
interruptions are not recommended because such an
approach may result in loss of response and
relapse/progression.
According
to
EHA
recommendations; patients with CML who discontinued
TKI for less than one year and who do not have access to
regular monitoring of CBC counts and BCR-ABL
transcripts in time of COVID-19 pandemic are suggested
to discuss with their doctors to restart TKI treatment6.
Furthermore, patients who have attempted treatmentfree remission (TFR) are in need of more frequent
monitoring, as often as monthly and require continuing if
at all possible. Initiation of TFR attempts may be
postponed during the COVID-19 pandemic due to the
increased requirement for monitoring that may not be
applicable6.
Patients with accelerated-phase CML responding well
to TKI may continue with proper monitoring.
Transformation to accelerated phase while on TKI can be
treated with a different TKI and close monitoring. Blast
phase CML should be treated with intensive
chemotherapy in combination with TKI if local conditions
allow for close monitoring, adequate supportive care
(blood product transfusion, management of possible
infections) and carefully weigh the risks and benefits6.
It is important to note that, attention should be given
to concomitant medications, which may interfere with TKI
metabolism in the face of a known COVID-19. Drug
interactions that may cause QT prolongation should be
taken into consideration when potential SARS-CoV-2
infection directed therapies given with TKI treatment and,
therefore, require proper EKG monitoring6.
4. Lymphoid neoplasms
4.1. Acute lymphoblastic leukemia
Treating patients with acute lymphoblastic leukemia
(ALL) in the time of COVID-19 pandemic can be
particularly challenging. The recent developments of ALL
treatments are based on less myelosupressive regimens
incorporating the CD3-CD19 bispecific antibody,
blinatumomab, and the anti-CD22 conjugated antibody,
inotuzumab ozogamicin [6]. These are advanced therapy
choices and overall safety and efficacy were shown in
numerous clinical trials, especially in elderly patients.
Sars-CoV-2 PCR testing should be performed
regardless of symptoms, including baseline CT of the chest
due to the potential for false-negative PCR from
nasopharyngeal swab, prior to induction as well as

consolidation treatment if indicated [6]. If the PCR testing
is positive, we should consider deferring treatment by 10–
14 days, except intrathecal therapies for CNS involvement.
If the patient is negative for SARS-CoV-2, consider
repeating the test after 24 h if there is high clinical
suspicion [9].
4.1.1. Ph-negative ALL
In ALL, one important question is the use of
glucocorticoids, as they still remain major components of
treatment protocols. There were concerns about their
possible role of viral rebound and adverse events in
COVID-19 time but results from a randomized clinical trial
enrolling patients with COVID-19 indicated that the use of
dexamethasone decreased mortality in hospitalized
patients requiring supplemental oxygen or mechanical
ventilation [10]. Despite these consequences, we should
still consider decreasing the steroid exposure in the
elderly population. Caution should be given to use of
asparaginase regarding the increased risk of thrombotic
complications of this drug and may mimic the COVID-19
related coagulopathies. The use of blinatumomab and
inotuzumab (with ursodeoxycholic acid as prophylaxis)
should not be deferred as their efficacy in terms of
survival has been established in the frontline setting
regardless of age [6]. It’s important to note that these
agents also minimize myelosupression and risk of COVID19. According to recommendations from a panel of
international experts, treatment with anti-CD20
monoclonal antibodies should be delayed if possible due
to hypogammaglobulinemia [9]. The decision to withhold
these agents should be made only in patients in which the
risk outweighs the benefit.
Consolidation with blinatumomab is considered if the
patients are positive for measurable residual disease
(MRD) after two cycles of chemotherapy. If the patients
achieved MRD negativity, advancement to maintenance
should be recommended [10]. The most of the ALL
protocols include 2 years of maintenance therapy after
induction/consolidation. As of March 19th 2020, GRAALL14 investigators recommended to omit vincristine and
prednisolone during maintenance, whilst continuing 6mercaptopurine and methotrexate [11]. For patients in
first CR, AHSCT can be postponed but the patients in
second CR should undergo AHSCT promptly as the risks of
relapse are high [12,13]. Inotuzumab could be given as the
first salvage therapy instead of blinatumomab for
administering outpatient treatment. It was also
recommended to delay CD19 CAR T-cell therapies. For
patients with relapsed or refractory ALL, each center
should carefully evaluate the risks and benefits of
pursuing a curative approach on a case-by-case basis [10].
4.1.2. Ph-positive ALL
TKIs are the backbone of the treatment. Second
generation TKI with reduced dose steroids are

American Society of Hematology (2020). Coronavirus Disease (COVID-19) and chronic myeloid leukemia: frequently asked
questions [online]. Website https://www.hematology.org/covid-19/covid-19-and-cml [accessed 25 September 2020].
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recommended to reduce the duration of hospital stay in
the COVID-19 time. One has to keep in mind to continue
administering a total of 12 intrathecal chemotherapies for
central nervous system prophylaxis [6].
4.2. Hairy cell leukemia
Most centers are using cladribine as an initial treatment of
patients with hairy cell leukemia. However, cladribine is
immunosuppressive, it’s important to avoid severe
neutropenia whenever possible to minimize the risk of
acquisition of SARS-CoV-2 [14]. Antibiotic prophylaxis
and G-CSF support are administered to shorten the period
of neutropenia and reduce the risk of a secondary
bacterial infection after viral infection.
4.3. Nonhodgkin lymphoma
4.3.1. Aggressive B-cell lymphomas
The diffuse large B-cell lymphoma (DLBCL) is the most
common aggressive lymphoma and majority of patients
with DLBCL require prompt treatment. Treatment of
newly diagnosed patients, often with intent to cure, has to
be shifted to outpatient setting whenever feasible. The
combination of rituximab with cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP)
continues to be the standard of care for DLBCL therapy
during the COVID-19 pandemic [15]. R-mini-CHOP with GCSF support may be used for the elderly patients. Four
cycles of R-CHOP rather than combined modality therapy
is recommended for limited stage (stage I/II) DLBCL if
PET-CT is negative at the end of treatment. None of the
experts have yet advised to change treatment for those
already receiving the treatment during COVID-19
pandemic [15]. It is acceptable to recommend
hypofractionation or omitting consolidation RT to
patients with bulky disease in those who are in complete
metabolic response after chemotherapy as reflected in the
International Lymphoma Radiation Oncology Group
Emergency Guidelines [16].
The primary mediastinal lymphoma (PML) is a
subgroup of aggressive lymphoma that has been reported
excellent results with R-DA-EPOCH. However, there is no
phase 3 randomized trial comparing R-CHOP and R-DAEPOCH. Hence, R-CHOP followed by radiotherapy (RT)
remains the standard therapy in the COVID-19 time [16].
Other aggressive lymphomas such as Burkitt’s lymphoma,
plasmablastic lymphoma, and lymphoblastic lymphoma,
the treatment strategy should not be changed based on
clinical and resources factors during the COVID-19
pandemic. These are highly aggressive lymphomas that
require prompt treatment despite of having high risk of
life-threatening complications [15].
Most experts do not recommend postponement of
chemotherapy in time of COVID-19 where the defer itself
is likely to adversely impact on patient’s outcome since
dose intensity and time are substantial [16].
Subcutaneous R should be advised to shorten patient time
in health care facilities [15]. G-CSF support may be
suggested to lighten neutropenia, and reduce the risk of
febrile neutropenia. Telemedicine is highly encouraged at
2804

most centers and defer medical appointments for patients
in CR or in patients in which no prompt change in therapy
is expected.
In the relapse setting, most experts are suggesting
outpatient regimens such as gemcitabine-based regimens
(rituximab, gemcitabine, cisplatin, and dexamethasone
(R-GDP)),
or
oxaliplatin-based
(rituximab,
dexamethasone, cytrabine, and oxaliplatin (R-DHAOX))
instead of R-DHAP (rituximab, dexamethasone,
cytarabine, cisplatin) or R-ICE (rituximab, ifosfamide,
carboplatin, etoposide) during COVID-19 pandemic [16].
The autologous stem-cell transplant (ASCT) should not be
postponed in patients with chemosensitive disease or at
least in partial response (PR) by CT scan. If there is no
complete metabolic response on PET-CT after salvage
therapy, the decision to proceed with ASCT should be
considered individually by taking into consideration
poorer outcome, especially in primary refractory disease
[16,17]. Some institutions may need to delay ASCT due to
lack of available ICU beds and blood shortages in COVID19 time. Lenalidomide-based regimen or polatuzumab
(approved in the third-line in the USA) with bendamustine
may be recommended in the relapse setting but it is
important to note that bendamustine dose reduction
should be considered due to high rates of febrile
neutropenia. In addition, off-label use of ibrutinib may be
also considered [4].
Treatment of post-ASCT relapses are challenging in the
COVID-19 time. CAR T-cell therapy and AHSCT are
resource intensive and severe immunosuppressive and
are likely to be less attainable [16,18].
4.3.2. Mantle cell lymphoma
As in the pre-COVID era, indolent mantle cell lymphoma
(MCL) with nonbulky disease and asymptomatic patients
may undergo a watch-and-wait strategy, including
symptom education and potentially surveillance imaging
[16]. For young and fit patients in need of prompt
treatment with aggressive MCL high-dose cytarabinebased induction therapy followed by ASCT and R
maintenance may be considered. No consensus was
achieved on R maintenance during the COVID-19
pandemic. If there is significant community transmission
of COVID-19, R maintenance should be avoided due to
increased risk of neutropenia and infection, without
proven overall survival benefit [16,17]. Controversially,
ASCT may need to be delayed in the setting of centers with
the limited capacity during COVID-19 outbreak. If ASCT is
decided to postpone, stem cell mobilization and collection
should be performed after 3–4 cycles of induction therapy
[16].
For elderly or unfit patients, bendamustine-rituximab
(BR), R-CHOP or rituximab with cyclophosphamide,
vincristine and prednisone (R-CVP) therapy with G-CSF
support may be suggested [16]. The benefit of R
maintenance after BR has not been clarified yet, therefore,
so not recommended in the current pandemic, but an OS
benefit with R maintenance after R-CHOP and after ASCT

CENGİZ SEVAL et al. / Turk J Med Sci
is well known [16]. Therefore, patients should be
evaluated individually.
In the relapsed setting, the centers should choice
regimens according to individual patient’s features and
pandemic evaluations. Based on this, oral drugs and
immunotherapy combinations may be preferred, such as
Bruton’s tyrosine kinase (BTK) inhibitors and
lenalidomide with R if not previously given. AHSCT should
be postponed in stable patient [16].
4.3.3. Indolent B-cell lymphomas
As in the pre-COVID-19 time, patients with indolent B-cell
NHL do not require prompt initiation of therapy unless
they have symptomatic nodal/extranodal disease, endorgan compromise or life-threating cytopenias [15]. If the
indication is borderline, the initiation of planned
treatment can be based on weighing risk-benefit ratio
between patient and physician, taking into account
disease features, in particular nonaggressive behavior of
disease, personalized infection risk and patient choice.
Therefore, a watch-and-wait approach might also be
preferred for oligo-symptomatic patients in order to avoid
immunosuppressive treatment during COVID-19
pandemic [15].
When treatment is indicated, protocols requiring the
least immunocompromise and fewest clinic visits should
be chosen during COVID-19 outbreak. For patients with
symptomatic sites of disease, limited palliative RT (4 Gy in
one to two fractions) should be considered with minimal
toxicity. Many experts are advising R-CVP (or
obinutuzumab-CVP for follicular lymphoma) or R-CHOP
(or obinutuzumab-CHOP for follicular lymphoma) with GCSF support and R maintenance. R monotherapy may also
be recommended to frail patients during COVID-19
pandemic [16,17].
For patients who have already obtained an excellent
response to chemoimmunotherapy, decreasing the
number of treatment cycles may be suggested or a change
of treatment to less immunosuppressive options in the
time of COVID-19. It is reasonable to defer R maintenance
to allow for faster B-cell recovery during the COVID-19
outbreak. Some experts have held R maintenance in
elderly patients and in younger patients with low
immunoglobulin (Ig) levels and suggest IVIG
supplementation if available [16]. Management of
relapsed/refractory indolent lymphoma should depend
on constitutional symptoms and indications for
treatment. Oral agents such as ibrutinib and lenalidomide
with rituximab should be considered but bendamustine
must be avoided because of its immunosuppressive
properties [15,16].
4.3.4. Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is usually a disease
of the elderly population associated with impaired

immunity even with early stage disease, and increased
risk for COVID-19 and related complications. In patients
not meeting International Workshop on chronic
lymphocytic leukemia (IWCLL) indications for treatment,
the watch-and-wait period should continue to be applied
[19]. Therefore, medical appointments for patients may
be postponed with a view to primary prevention by
minimizing potential exposure. Telemedicine and local
laboratories are highly encouraged during COVID-19
outbreak.
In patients in need of immediate therapy, the best
treatment option should be based on individual factors
including symptom burden and comorbidities, along with
molecular and cytogenetic abnormalities [7]. If
reasonable, initiation of new therapies to patients with
CLL should be deferred to minimize the number of
hospital visits and potential hospitalization in the
presence of this pandemic. One has to keep in mind that
treatment should be considered to delay in oligosymptomatic patients, as well as patients with nonlife
threatening cytopenias.
Fludarabine, cyclophosphamide, and rituximab (FCR)
combination is the standard chemotherapy regimen in fit
patients with CLL [20]. However, during COVID pandemic
FCR may not be preferred due to significant
immunosuppression, including grade 3/4 cytopenia and
febrile neutropenia [21]. If the patient is already treated
with FCR, early cessation of treatment may be considered
after 3–4 cycles because of clinically significant treatmentrelated cytopenias or achieved disease control [20]. There
was no consensus on using BR (bendamustine, rituximab)
instead of FCR in patients in need of therapy in time of
COVID-19. In addition, the use of monoclonal antibodies
(rituximab and obinutuzumab) should be avoided or
skipped if convenient, because of B-cell depletion which
may potentially reduce the humoral response to virus
[20,21].
The management of CLL treatment has moved into
highly effective oral targeted therapies over the past few
years. In the era of COVID-19 pandemic, we should
consider to use the novel oral therapies, including
ibrutinib, acalabrutinib, and venetoclax, both in the newly
diagnosed and relapsed settings, especially in patients
with high-risk cytogenetics (del17p and TP53
disruption)8. It is important to note that ibrutinib and
acalabrutinib are generally well tolerated and limit the
time spent in the clinic and resource utilization at the time
of treatment initiation compared with the venetoclax and
obinituzumab combination. When considering venetoclax
in combination with anti-CD20 therapy, it is
recommended to defer rituximab/obinutuzumab and
administer venetoclax as monotherapy [21]. However,
venetoclax requires tumour lysis syndrome (TLS)
monitoring and leads to higher rates of FEN than
treatment with BTK inhibitors. On the other hand, BTK
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inhibitors may cause atrial fibrillation and an increased
risk of bleeding and one has to keep in mind that patients
with severe COVID-19 often develop severe
thrombocytopenia [10,11].
If the CLL patients are currently on an oral targeted
treatment without any complications, it’s recommended
to continue with the same therapy7 [6,10,11]. We have to
emphasize that BTK inhibition may compromise innate
immune response as well as T and B-cell functions
resulting in a decreased cellular and humoral immune
response to SARS-CoV-2 [22]. Treon and his colleagues
had reported that BTK inhibition could lead to inhibition
of cytokine production and potentially decrease the risk of
hyperinflammation associated with COVID-19. Based on
these results, ibrutinib and acalabrutinib are now being
investigated for the treatment of cytokine release
syndrome associated with COVID-19 [17].
In CLL patients, IVIG treatment is considered to
continue during COVID-19 pandemic. But it is reasonable
to suggest less frequent infusions (e.g., every 6–8 weeks)
targeting an IgG level of 400–500 mg/dL. In addition,
given the increased risk of thromboembolic events in the
patients with COVID-19, it is recommended to weigh the
risk and benefits for each patient and to monitor closely
for thromboembolic symptoms7.
Currently, there is not enough evidence to recommend
changing the specific classes of targeted CLL drugs in
patients infected with SARS-CoV-2 and discontinuation or
continuing treatment decisions should be made on caseby-case basis.
4.4. Hodgkin’s lymphoma
It is recommended not to delay the treatment of HL during
COVID-19 outbreak [19]. However, since there is no clear
consensus on the role of more intensive regimens that
consume more resources in time of COVID-19, ABVD has
been considered the good choice as initial treatment [15].
Of note, pulmonary toxicity associated with bleomycin
may become a risk factor for those who acquire COVID-19
and also may mimic the symptoms of COVID-19 [16].
Regarding relapsed patients with HL, outpatient
salvage chemotherapy protocols should be considered
including gemcitabine-based regimens or novel agents
such as brentuximab vedotin (BV) and checkpoint
inhibitors (CPI) (nivolumab) [6,15,16]. In addition, it is
not recommended to postpone the ASCT depending upon
accessibility, due to the chance of cure [14]. There is no
clear consideration for BV consolidation in the COVID-19
outbreak. A novel agent (BV or CPI) might be preferred in
the second-line salvage setting or transplant-ineligible
patients [15,16]9. But it is important to mention that the
risk of pulmonary toxicity with CPI in the time of COVID19 is unknown.
5. Multiple myeloma
The median age at diagnosis for myeloma patients is 69
years and elderly patients are more susceptible to have
comorbidities compromising the immune system [23]. In
9

particular, these patients have significant immune
dysfunction and an uncontrolled malignant clone affecting
the host immunity by suppressing normal B-cell
development and function long before the MM diagnosis
[24]. The overall tumor burden, as shown by laboratory
and imaging studies, and the previous history of
asymptomatic long-standing paraproteinemia should also
be taken into consideration. One has to keep in mind that
myeloma drugs such as immunomodulatory drugs (IMID)
and proteasome inhibitors (PIs) also cause more
immunosuppression and contribute more infections
[25,26].
Prophylaxis against varicella-zoster virus and
pneumocystis jirovecii are required for myeloma patients.
Levofloxacin prophylaxis for the first three months of
induction treatment is also highly recommended [27]. In
addition, myeloma patients are at an increased risk for
thromboembolism that may alter in accordance with
patient,
disease
status,
or
treatment-related
characteristics and may be aggravated with SARS-CoV-2
infection that promotes a hypercoagulation state as well
[28]. Prophylactic anticoagulation should be given
according to local or international guidelines and lowmolecular-weight heparin (LMWH) may be taken into
consideration for countries with high incidence of COVID19 in myeloma patients under IMIDs regardless of their
thrombotic risk [29].
5.1. Monoclonal gammopathy of undetermined
significance and smoldering MM
There is no disagreement regarding the management of
patients with monoclonal gammopathy of undetermined
significance (MGUS) and standard-risk smoldering MM
(SMM). These patients should be followed up long-term
with no active intervention. For high-risk patients,
encouraging results with lenalidomide was established
but this has not change the clinical practice outside clinical
trials in most countries [29,30]. We currently believe that
including these patients in clinical trials is the best
strategy but because of the current pandemic situation,
many trials closed the new patient administration so we
would advise close monitoring of these patients for
development of symptomatic disease requiring therapy.
5.2. Newly diagnosed MM
According to the European Myeloma Network (EMN)
recommendations, induction therapies should not be
postponed for newly diagnosed MM (NDMM) patients
with active disease. It was suggested to screen all patients
for SARS-CoV-2 infection before initiating therapy as
myeloma treatment can aggravate the adverse events of
an active COVID-19. For myeloma patients testing positive
for SARS-CoV-2, holding therapy was recommended until
they have convalesced from acute disease [29]. Standard
firstline treatment using bortezomib, cyclophosphamide,
and dexamethasone (VCD) or bortezomib, lenalidomide,
and dexamethasone (VRD) should be considered [24,29].
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We want to point out that subcutaneously once a week
bortezomib administration might be preferred rather
than intravenously or twice a week. In addition, the dose
of dexamethasone should be reduced to 20 mg weekly
[23]. Oral drugs combinations (ixazomib, lenalidomide,
and
dexamethasone
(IRd);
cyclophosphamide,
lenalidomide, and dexamethasone (CRd)) may also be
used in NDMM patients to reduce the risk of weekly clinic
visits and exposure [25,30]. It’s important to note that
these regimens have not been compared head to head
with known standard treatment options, but the response
rates from early phase trials are comparable. In the
maintenance setting, oral therapies which will reduce
hospital visits should be preferred as much as possible.
5.2.1. Transplant-eligible NDMM
In considering, the anticipated immunosuppression
following ASCT, it is suggested to delay mobilization, stem
cell harvest, conditioning and ASCT, particularly in
patients with standard risk disease [28]. Physicians may
also postpone ASCT in patients with marginal fitness due
to age or comorbidities [29]. In case of close contact with
a person infected with SARS-CoV-2, a deferral of the stem
cell harvests and any transplant procedure is
recommended until at least 14 days, and preferably 21
days from the last contact. In addition, patients should be
closely monitored for the presence of COVID-19 with
confirmed PCR negativity before transplant procedure is
undertaken3.
In myeloma patients diagnosed with COVID-19, ASCT
should be delayed until the patient is asymptomatic and
has two negative PCR swabs taken at least 24 h apart. In
patients with moderate to severe COVID-19, it can be
considered to allow enough time for the lung function and
general performance to reach to pre-COVID-19 values3.
Patients who are stable on maintenance with no major
side effects should continue on their treatment. If the
patient is on dexamethasone, tapering it down may be
considered. In addition, these patients should visit the
clinic every 3 months [28]. Monitoring should be planned
in the closest laboratory and phone visits may be used for
toxicity control.
5.2.2. Transplant-ineligible NDMM
All-oral regimens (e.g. lenalidomide with dexamethasone
(Rd)) should be considered in order to minimize hospital
visits. Dexamethasone can be reduced to 20 mg weekly
and even de-escalation (or even interruption) should be
considered for responding myeloma patients [24,29,32].
5.2.3. Relapsed/refractory disease
Depending on the COVID-19 prevalence and available
clinical resources in the community, monthly close
monitoring may be advised for biochemical relapses,
especially for patients with a slow increase in the
paraprotein level [29]. Otherwise, patients with refractory
disease, new onset of CRAB features (hypercalcemia, renal
failure, anemia, and bone disease) or those with a
biochemical relapse and a history of aggressive relapse
with impairment of the clinical presentation will require

next-line, immediate treatment. Regarding the selection of
treatment protocol, orally given agents should be advised
[29].
Myeloma patients diagnosed with COVID-19 should be
treated as per standard guidelines starting from isolation
measures. Asymptomatic patients for COVID-19 should be
quarantined at home for at least 14 days, under close
surveillance for determining COVID-19-associated signs
and symptoms, in such cases antimyeloma therapy should
be deferred [28]. In patients with CRAB signs or other
aggressive myeloma features, treatment should not be
delayed [24,29]. One has to keep in mind that steroids
and/or other drugs inducing lymphopenia should be
discontinued.
In the event of emergence of symptomatic infection,
treatment might be hold and steroids should be tapered
down with the goal of discontinuation until full recovery
from COVID-19 [24,29]. For patients enrolled in a clinical
trial, investigational agents should be withdrawn until
COVID-19 resolution and the reporting should be done
with the corresponding guidelines. In general, COVID-19
infection is reported as an adverse event of special
interest unless it fulfills the well-established criteria for a
serious adverse event [29].
Myeloma patients are administered several drugs for
supportive care in addition to drugs with direct
antimyeloma activity. Caution should be given to
polypharmacy. Many agents that are being evaluated
against SARS-CoV-2 (hydroxychloroquine, azithromycin
and remdesivir) may have significant interactions with
other drugs and may result in significant hepatic, cardiac
or renal toxicity [33,34,35]. Hence, close monitoring of
organ functions is important.
6. Conclusions
The COVID-19 pandemic represents a tremendous
challenge and has been an unusual historic pandemic of
recent times. This pandemic created an unprecedented
medical, logistical, financial, and public health hurdles to
the delivery of optimal care for patients with hematologic
malignancies. Because of either the primary malignancy
or the severe myelosuppression and lymphodepletion due
to chemotherapy regimens, patients with hematologic
malignancies have an increased risk of SARS-CoV-2
infection and severe COVID-19 disease [11]. Curative
therapy for many patients with hematologic malignancies
includes a dose intensive chemo-radiation protocols
followed by ASCT or AHSCT [36]. Therefore, COVID-19
pandemic is currently an important challenge in the
setting of treatment of hemato-oncological malignancies
[37]. The technologic explosion of telemedicine and home
care platforms are highly encouraged at most centers and
defer medical appointments for patients in CR or in
patients in which no prompt change in therapy is
expected. While routine elective procedures have been
postponed for a while, scheduling and performance of the
diagnostic tests, staging, and chemotherapy clearance
procedures have continued [11]. In some cases, what was
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once thought to be impossible has become a normal
routine. COVID-testing platforms have been spread
remarkably. Clinical trial operations have remained open,
if scaled down, in many institutions during the pandemic,
and study logistics, including consenting, sample
acquisition and transportation as well as study visits have
been made more flexible. While the peak of the pandemic
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